Table 2.

Expansion kinetics and viability of cervical cytobrush and blood-derived T-cell lines using Dynal anti-CD3/28 T-cell expander beads

PID	Cervical T cells					Blood T cells
	Ex vivo recovery (×106 cells)	Ex vivo viability (%)	Expanded recovery (×106 cells)	Ex vivo viability (%)	Fold expansion (Day 14:Day 0)	Ex vivo recovery (×106 cells)	Ex vivo viability (%)	Expanded recovery (×106 cells)	Ex vivo viability (%)	Fold expansion (Day 14:Day 0)
1	0·17	88	2·92	90	17·4	0·1	98	5·05	98	50·5
2	0·08	88	1·24	78	15·7	0·1	100	3·35	88	23·5
3	0·11	85	1·58	94	14·8	0·1	98	3·35	98	23·5
4	0·09	92	1·27	80	14·3	0·1	100	3·12	92	21·2
5	0·13	98	1·31	88	10·3	0·1	100	3·55	89	25·5
6	0·19	90	2·87	85	15·0	0·1	98	5·50	84	65·0
7	0·14	92	2·69	94	19·2	0·1	96	3·37	96	33·7
8	0·10	98	1·29	80	12·5	0·1	98	4·89	98	28·9
9	0·12	96	2·09	80	17·3	0·1	100	3·89	92	28·9
10	0·11	80	1·45	80	12·9	0·1	97	3·61	86	36·1
11	0·13	89	2·69	90	20·5	0·1	100	3·16	100	31·6
12	0·11	90	1·45	90	13·3	0·1	96	3·26	94	32·6
13	0·09	90	1·20	76	13·0	0·1	99	3·60	89	26·0
14	0·12	85	2·10	78	16·8	0·1	99	3·74	88	37·4
15	0·12	98	1·94	84	16·7	0·1	99	3·91	88	29·1
16	0·08	90	1·94	94	25·5	0·1	99	2·91	92	19·1
Meadian	0·11	90	1·76	84·5	15·4	0·1	99	3·57	92	29·0
IQR	0·10	88	1·31	80	13·2	0·1	98	3·32	88	25·0
IQR	0·13	93	2·25	90	17·3	0·1	100	3·90	96·5	34·3